DEF 14A: Quoin Pharmaceuticals Seeks Shareholder Approval for $8 Million Alumni Capital Equity Line

Quoin Pharmaceuticals is asking shareholders to approve the issuance of shares related to an $8 million purchase agreement with Alumni Capital LP at a special general meeting on March 29, 2024.

Summary

• Quoin Pharmaceuticals is holding a Special General Meeting of Shareholders on March 29, 2024, to seek approval for the issuance of ordinary shares represented by American Depositary Shares (ADSs) related to a purchase agreement with Alumni Capital LP.
• The agreement, dated January 25, 2024, allows Quoin to sell up to $8 million of newly issued ADSs to Alumni Capital, subject to certain conditions and limitations.
• Shareholder approval is required to comply with Nasdaq Listing Rule 5635(d), which necessitates approval for transactions involving the issuance of shares equal to 20% or more of the outstanding shares or voting power at a price below a specified minimum.
• The board of directors recommends voting FOR the Alumni Issuance Proposal.
• If the proposal is not approved, Quoin will be unable to utilize the Purchase Agreement with Alumni Capital and may need to seek alternative financing.
• As of February 23, 2024, there were 987,220 ordinary shares issued and outstanding, each represented by one ADS.
• The meeting will be held at Blank Rome LLP in Philadelphia, PA, at 12:00 p.m. U.S. Eastern Time.

Sentiment

Score: 6

Explanation: The document is a standard proxy statement, so the sentiment is neutral. The equity line provides potential funding, but also carries dilution risks.

Positives

• The Alumni Capital agreement provides Quoin with a potential reliable source of capital up to $8 million.
• There are no restrictions on future financings, rights of first refusal, participation rights, penalties or liquidated damages in the Purchase Agreement.
• Alumni has agreed not to engage in short selling or hedging of the ADSs during the term of the Purchase Agreement.
• The company has agreed to issue purchase notices for an aggregate of at least $4,000,000 of the Commitment Amount prior to the end of the Commitment Period.

Negatives

• The issuance of ADSs to Alumni will have a dilutive effect on existing shareholders, potentially impacting voting power and economic rights.
• Sales of ADSs by Alumni in the public market could adversely affect the prevailing market prices of Quoin's ADSs.
• If the Alumni Issuance Proposal is not approved, the Company may need to seek alternative sources of financing, which financing may not be available on advantageous terms, or at all, and which may result in the incurrence of additional transaction expenses.

Risks

• Failure to obtain shareholder approval for the Alumni Issuance Proposal could hinder Quoin's ability to raise capital.
• The market price of Quoin's ADSs could be negatively impacted by the issuance of new shares to Alumni and subsequent sales in the market.
• The actual amount of proceeds raised under the Purchase Agreement will depend on market conditions and the company's decisions regarding the timing and amount of sales to Alumni.

Future Outlook

Quoin plans to use any proceeds from the sale of ADSs to Alumni for strategic opportunities, research and development activities, working capital, and other general corporate purposes.

Management Comments

• Our Board has determined that the Purchase Agreement and our ability to issue our ADSs to Alumni pursuant to the Purchase Agreement is in the best interests of the Company and its shareholders because the Purchase Agreement provides us with a reliable source of capital.

Industry Context

Many small-cap biotech companies utilize equity lines of credit as a flexible financing mechanism to fund operations and research. The terms of these agreements can vary significantly, impacting the potential dilution and cost of capital.

Comparison to Industry Standards

• Similar equity lines of credit are used by companies like Aeterna Zentaris Inc. and Evofem Biosciences Inc. to secure funding.
• The specific terms, such as the discount to market price and the commitment fee, are comparable to industry standards, but the impact on shareholders depends on the frequency and size of drawdowns.
• The absence of restrictions on future financings is a positive aspect compared to some agreements that may include restrictive covenants.

Stakeholder Impact

• Shareholders will be impacted by the potential dilution from the issuance of new ADSs.
• The company's ability to fund its operations and research and development activities will be affected by the availability of capital from the Alumni Capital agreement.
• Employees may be impacted by the company's ability to execute its business plans and strategic opportunities.

Next Steps

• Shareholders need to vote on the Alumni Issuance Proposal before the Special General Meeting on March 29, 2024.
• The company will file a Current Report on Form 8-K with the SEC to announce the voting results after the meeting.
• Quoin will need to file a registration statement with the SEC to register for resale the ADSs that may be issued to Alumni under the Purchase Agreement.

Key Dates

Keywords

Alumni Capital LP, ADSs, shareholder approval, equity financing, Quoin Pharmaceuticals, issuance proposal, proxy statement